Vikram Thermo India [VIKRAMTH] vs Aarti Drugs [AARTIDRUGS] Detailed Stock Comparison

Vikram Thermo India
BSE
Loading...

Aarti Drugs
NSE
Loading...
TLDR: Quick Comparison Summary
Based on 20 vital metrics comparison: Vikram Thermo India wins in 8 metrics, Aarti Drugs wins in 11 metrics, with 0 ties. Aarti Drugs appears stronger overall.
View Metrics Details
Vital Metrics Comparison
Metric | Vikram Thermo India | Aarti Drugs | Better |
---|---|---|---|
P/E Ratio (TTM) | 54.85 | 23.59 | Aarti Drugs |
Price-to-Book Ratio | 3.81 | 3.25 | Aarti Drugs |
Debt-to-Equity Ratio | 5.27 | 44.92 | Vikram Thermo India |
PEG Ratio | N/A | 0.37 | N/A |
EV/EBITDA | 10.60 | 17.02 | Vikram Thermo India |
Profit Margin (TTM) | 25.77% | 7.80% | Vikram Thermo India |
Operating Margin (TTM) | 37.09% | 10.11% | Vikram Thermo India |
EBITDA Margin (TTM) | 37.09% | 10.11% | Vikram Thermo India |
Return on Equity | 6.67% | 12.28% | Aarti Drugs |
Return on Assets (TTM) | 5.55% | 6.53% | Aarti Drugs |
Free Cash Flow (TTM) | $-159.87M | $674.20M | Aarti Drugs |
Dividend Yield | 0.47% | 0.22% | Vikram Thermo India |
1-Year Return | -19.33% | -2.04% | Aarti Drugs |
Price-to-Sales Ratio (TTM) | 3.74 | 1.83 | Aarti Drugs |
Enterprise Value | $4.69B | $50.34B | Aarti Drugs |
EV/Revenue Ratio | 3.79 | 2.08 | Aarti Drugs |
Gross Profit Margin (TTM) | 58.07% | 36.77% | Vikram Thermo India |
Revenue per Share (TTM) | $39 | $265 | Aarti Drugs |
Earnings per Share (Diluted) | $2.69 | $20.63 | Aarti Drugs |
Beta (Stock Volatility) | -0.23 | 0.21 | Vikram Thermo India |
Performance
Key Stats
Valuation
Financials
Short Interest
Dividends
Vikram Thermo India vs Aarti Drugs Stock Performance Analysis
Loading Price Chart...
Performance Comparison
Short-term Returns
Stock | 1D | 1W | 1M | 3M | 6M | YTD |
---|---|---|---|---|---|---|
Vikram Thermo India | 2.68% | 0.14% | -2.67% | -16.66% | -23.41% | -15.52% |
Aarti Drugs | 3.53% | -3.86% | 1.23% | 5.23% | 18.26% | 6.84% |
Long-term Returns
Stock | 1Y | 3Y | 5Y | 10Y | 15Y | 20Y |
---|---|---|---|---|---|---|
Vikram Thermo India | -19.33% | 216.97% | -23.09% | 114.46% | 542.92% | 432.67% |
Aarti Drugs | -2.04% | 8.97% | -37.88% | 208.08% | 2,669.78% | 2,338.13% |
Performance & Financial Health Analysis: Vikram Thermo India vs Aarti Drugs
Metric | VIKRAMTH | AARTIDRUGS |
---|---|---|
Market Information | ||
Market Cap | ₹4.63B | ₹44.42B |
Market Cap Category | Small cap | Small cap |
10 Day Avg. Volume | 10,318 | 159,509 |
90 Day Avg. Volume | 9,094 | 613,674 |
Last Close | ₹151.50 | ₹503.85 |
52 Week Range | ₹126.85 - ₹216.45 | ₹312.00 - ₹635.00 |
% from 52W High | -30.01% | -20.65% |
All-Time High | ₹311.00 (Apr 25, 2022) | ₹1,026.95 (Oct 05, 2020) |
% from All-Time High | -51.29% | -50.94% |
Growth Metrics | ||
Quarterly Revenue Growth | -0.08% | 0.06% |
Quarterly Earnings Growth | -0.10% | 0.62% |
Financial Health | ||
Profit Margin (TTM) | 0.26% | 0.08% |
Operating Margin (TTM) | 0.37% | 0.10% |
Return on Equity (TTM) | 0.07% | 0.12% |
Debt to Equity (MRQ) | 5.27 | 44.92 |
Cash & Liquidity | ||
Book Value per Share (MRQ) | ₹38.75 | ₹149.84 |
Cash per Share (MRQ) | ₹0.17 | ₹2.48 |
Operating Cash Flow (TTM) | ₹324.18M | ₹2.83B |
Levered Free Cash Flow (TTM) | ₹80.99M | ₹1.68B |
Dividends | ||
Last 12-Month Dividend Yield | 0.47% | 0.22% |
Last 12-Month Dividend | ₹0.75 | ₹1.00 |
Valuation & Enterprise Metrics Analysis: Vikram Thermo India vs Aarti Drugs
Metric | VIKRAMTH | AARTIDRUGS |
---|---|---|
Price Ratios | ||
P/E Ratio (TTM) | 54.85 | 23.59 |
Forward P/E | N/A | 14.97 |
PEG Ratio | N/A | 0.37 |
Price to Sales (TTM) | 3.74 | 1.83 |
Price to Book (MRQ) | 3.81 | 3.25 |
Market Capitalization | ||
Market Capitalization | ₹4.63B | ₹44.42B |
Enterprise Value | ₹4.69B | ₹50.34B |
Enterprise Value Metrics | ||
Enterprise to Revenue | 3.79 | 2.08 |
Enterprise to EBITDA | 10.60 | 17.02 |
Risk & Other Metrics | ||
Beta | -0.23 | 0.21 |
Book Value per Share (MRQ) | ₹38.75 | ₹149.84 |
Financial Statements Comparison: Vikram Thermo India vs Aarti Drugs
Financial Metrics
Loading Financial Charts...
Revenue
EBITDA
Operating Margin
Free Cash Flow
Long Term Debt
Profit Margin
Current Ratio
Operating Cash Flow
Income Statement (MRQ)
Metric (MRQ) | VIKRAMTH | AARTIDRUGS |
---|---|---|
Revenue/Sales | ₹271.07M | ₹6.77B |
Cost of Goods Sold | ₹113.67M | ₹4.37B |
Gross Profit | ₹157.40M | ₹2.40B |
Research & Development | N/A | N/A |
Operating Income (EBIT) | ₹65.96M | ₹784.50M |
EBITDA | ₹77.14M | ₹951.90M |
Pre-Tax Income | ₹69.25M | ₹711.50M |
Income Tax | ₹28.50M | ₹83.80M |
Net Income (Profit) | ₹40.75M | ₹627.70M |
Balance Sheet & Liquidity Metrics (MRQ)
Metric (MRQ) | VIKRAMTH | AARTIDRUGS |
---|---|---|
Cash & Equivalents | ₹1.62M | ₹45.80M |
Total Current Assets | ₹627.63M | ₹13.38B |
Total Current Liabilities | ₹200.68M | ₹8.37B |
Long-Term Debt | ₹21.88M | ₹2.86B |
Total Shareholders Equity | ₹1.21B | ₹13.69B |
Retained Earnings | N/A | N/A |
Property, Plant & Equipment | ₹449.22M | ₹8.59B |
Cash Flow Statement Comparison (MRQ)
Metric (MRQ) | VIKRAMTH | AARTIDRUGS |
---|---|---|
Operating Cash Flow | N/A | N/A |
Capital Expenditures | N/A | N/A |
Free Cash Flow | N/A | N/A |
Debt Repayment | N/A | N/A |
Common Stock Repurchase | N/A | N/A |
Short Interest & Institutional Ownership Analysis
Metric | VIKRAMTH | AARTIDRUGS |
---|---|---|
Shares Short | N/A | N/A |
Short Ratio | N/A | N/A |
Short % of Float | N/A | N/A |
Average Daily Volume (10 Day) | 10,318 | 159,509 |
Average Daily Volume (90 Day) | 9,094 | 613,674 |
Shares Outstanding | 31.36M | 91.27M |
Float Shares | 8.20M | 35.46M |
% Held by Insiders | 0.69% | 0.61% |
% Held by Institutions | 0.00% | 0.11% |
Dividend Analysis & Yield Comparison: Vikram Thermo India vs Aarti Drugs
Metric | VIKRAMTH | AARTIDRUGS |
---|---|---|
Last 12-Month Dividend | ₹0.75 | ₹1.00 |
Last 12-Month Dividend Yield | 0.47% | 0.22% |
3-Year Avg Annual Dividend | ₹0.52 | ₹1.00 |
3-Year Avg Dividend Yield | 0.52% | 0.23% |
3-Year Total Dividends | ₹1.55 | ₹3.00 |
Ex-Dividend Date | Sep 23, 2024 | Feb 04, 2025 |